Trillium Therapeutics Inc. – TSX:TRIL.TO

Trillium Therapeutics stock price today

CAD 23.33

Trillium Therapeutics stock price quarterly change

+5.38%
quarter

Trillium Therapeutics stock price yearly change

+29.39%
year

Trillium Therapeutics key metrics

Market Cap
 N/A
Enterprise value
 2.35B
P/E
 -34.05
EV/Sales
 54737.23
EV/EBITDA
 35.95
Price/Sales
 56890.09
Price/Book
 10.06
PEG ratio
 -0.59
EPS
 0.82
Revenue
 N/A
EBITDA
 65.46M
Income
 65.08M
Revenue Q/Q
 N/A
Revenue Y/Y
 -62.39%
Profit margin
 151351.16%
Oper. margin
 -161183.72%
Gross margin
 0%
EBIT margin
 -161183.72%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Trillium Therapeutics stock price history

Trillium Therapeutics stock forecast

Trillium Therapeutics financial statements

Profit Margin

Trillium Therapeutics Inc. (TSX:TRIL.TO): Profit margin
Dec 2020 33K 113.65M 344418.18%
Mar 2021 0 -10.86M
Jun 2021 10K -18.39M -183990%
Sep 2021 0 -19.31M
TRIL.TO income statement history

Debt to Assets

Trillium Therapeutics Inc. (TSX:TRIL.TO): Debt to assets
Dec 2020 300822000 21.97M 7.3%
Mar 2021 288288000 15.30M 5.31%
Jun 2021 273684000 14.11M 5.16%
Sep 2021 265360000 22.19M 8.37%
TRIL.TO balance sheet history

Cash Flow

Trillium Therapeutics Inc. (TSX:TRIL.TO): Cash Flow
Dec 2020 -5.19M 11.52M 3.78M
Mar 2021 -17.07M 15.76M 1.63M
Jun 2021 -11.48M -67.38M 895K
Sep 2021 -13.98M -62.73M 112K
TRIL.TO cash flow history

Trillium Therapeutics alternative data

Trillium Therapeutics
Employees

Trillium Therapeutics Inc. (TSX:TRIL.TO): Employee count
Aug 2023 33
Sep 2023 33
Oct 2023 33
Nov 2023 33
Dec 2023 33
Jan 2024 33
Feb 2024 33
Mar 2024 33
Apr 2024 33
May 2024 33
Jun 2024 33
Jul 2024 33

Trillium Therapeutics other data

Frequently Asked Questions (FAQ)

  • What's the price of Trillium Therapeutics stock today?

    One share of Trillium Therapeutics stock can currently be purchased for approximately $23.33.

  • When is Trillium Therapeutics's next earnings date?

    Unfortunately, Trillium Therapeutics's (TRIL.TO) next earnings date is currently unknown.

  • Does Trillium Therapeutics pay dividends?

    No, Trillium Therapeutics does not pay dividends.

  • What is Trillium Therapeutics's stock symbol?

    Trillium Therapeutics Inc. is traded on the TSX under the ticker symbol "TRIL.TO".

  • What is Trillium Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Trillium Therapeutics?

    Shares of Trillium Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does Trillium Therapeutics have?

    As Jul 2024, Trillium Therapeutics employs 33 workers.

  • When Trillium Therapeutics went public?

    Trillium Therapeutics Inc. is publicly traded company for more then 11 years since IPO on 22 Apr 2014.

  • What is Trillium Therapeutics's official website?

    The official website for Trillium Therapeutics is trilliumtherapeutics.com.

  • Where are Trillium Therapeutics's headquarters?

    Trillium Therapeutics is headquartered at 2488 Dunwin Drive, Mississauga, ON.

  • How can i contact Trillium Therapeutics?

    Trillium Therapeutics's mailing address is 2488 Dunwin Drive, Mississauga, ON and company can be reached via phone at +41 65950627.

Trillium Therapeutics company profile:

Trillium Therapeutics Inc.

trilliumtherapeutics.com
Exchange:

TSX

Full time employees:

33

Industry:

Biotechnology

Sector:

Healthcare

Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. Its product candidates also include TTI-622 that is in Phase I clinical trial of immunoglobulin G4 SIRPaFc protein; and TTI-10001, a small molecule stimulator of interferon genes agonist that senses cytosolic DNA for promoting tumor immunity, which is in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 is headquartered in Mississauga, Canada.

+41 65950627
2488 Dunwin Drive
Mississauga, ON 02140

:
ISIN: CA89624T1057
CUSIP: 89624T105